12:00 AM
Feb 02, 2004
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Thymitaq nolatrexed: Phase III

Eximias said an independent data safety monitoring board (DSMB) unanimously recommended that the international Phase III (ETHECC) liver cancer trial continue. Eximias said the DSMB...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >